Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 12;17(1):339.
doi: 10.1186/s12879-017-2313-0.

Early morning urine collection to improve urinary lateral flow LAM assay sensitivity in hospitalised patients with HIV-TB co-infection

Phindile Gina  1 , Philippa J Randall  1 , Tapuwa E Muchinga  1 , Anil Pooran  1 , Richard Meldau  1 , Jonny G Peter  1 , Keertan Dheda  2   3
Affiliations

Early morning urine collection to improve urinary lateral flow LAM assay sensitivity in hospitalised patients with HIV-TB co-infection

Phindile Gina et al. BMC Infect Dis. .

Abstract

Background: Urine LAM testing has been approved by the WHO for use in hospitalised patients with advanced immunosuppression. However, sensitivity remains suboptimal. We therefore examined the incremental diagnostic sensitivity of early morning urine (EMU) versus random urine sampling using the Determine® lateral flow lipoarabinomannan assay (LF-LAM) in HIV-TB co-infected patients.

Methods: Consenting HIV-infected inpatients, screened as part of a larger prospective randomized controlled trial, that were treated for TB, and could donate matched random and EMU samples were included. Thus paired sample were collected from the same patient, LF-LAM was graded using the pre-January 2014, with grade 1 and 2 manufacturer-designated cut-points (the latter designated grade 1 after January 2014). Single sputum Xpert-MTB/RIF and/or TB culture positivity served as the reference standard (definite TB). Those treated for TB but not meeting this standard were designated probable TB.

Results: 123 HIV-infected patients commenced anti-TB treatment and provided matched random and EMU samples. 33% (41/123) and 67% (82/123) had definite and probable TB, respectively. Amongst those with definite TB LF-LAM sensitivity (95%CI), using the grade 2 cut-point, increased from 12% (5-24; 5/43) to 39% (26-54; 16/41) with random versus EMU, respectively (p = 0.005). Similarly, amongst probable TB, LF-LAM sensitivity increased from 10% (5-17; 8/83) to 24% (16-34; 20/82) (p = 0.001). LF-LAM specificity was not determined.

Conclusion: This proof of concept study indicates that EMU could improve the sensitivity of LF-LAM in hospitalised TB-HIV co-infected patients. These data have implications for clinical practice.

Keywords: Determine® lateral flow lipoarabinomannan assay (LF-LAM); Early morning urine (EMU); TB HIV co-infection.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart showing study population, Xpert/culture status and diagnostic groups
Fig. 2
Fig. 2
Overall sensitivity of the urine LAM strip test using random versus EMU samples and stratified by CD4 count
See this image and copyright information in PMC

References

    1. Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet. 2016;387(10024):1187–97. doi: 10.1016/S0140-6736(15)01092-2. - DOI - PubMed
    1. Holtz TH, Kabera G, Mthiyane T, Zingoni T, Nadesan S, Ross D, et al. Use of a WHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis. 2011;11(7):533–40. doi: 10.1016/S1473-3099(11)70057-3. - DOI - PubMed
    1. Peter JG, Theron G, Dheda K. Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons. PLoS One. 2013;8(2):e54875. doi: 10.1371/journal.pone.0054875. - DOI - PMC - PubMed
    1. Young BL, Mlamla Z, Gqamana PP, Smit S, Roberts T, Peter J, et al. The identification of tuberculosis biomarkers in human urine samples. Eur Respir J. 2014;43(6):1719–29. doi: 10.1183/09031936.00175113. - DOI - PubMed
    1. Savolainen L, Kantele A, Sandboge B, Sirén M, Valleala H, Tuompo R, et al. Modification of clearview tuberculosis (TB) enzyme-linked immunosorbent assay for TB patients not infected with HIV. Clin Vaccine Immunol. 2013;20(9):1479–82. doi: 10.1128/CVI.00375-13. - DOI - PMC - PubMed